Nanologica will participate in the virtual partnering event Partnering Against COVID-19 on May 4 – 6.
The aim of the event is to support the fight against COVID-19 and to accelerate global collaboration. Participating parties will consist of organizations working with solutions for COVID-19 testing, treatment and prevention.
“In these difficult times, we are excited to take part of such an important event. Our inhalation technology is still in early stages but has the potential to be an interesting platform for formulating drugs targeting COVID-19, as well as other diseases affecting the lungs. If we could in any way contribute to the fight against COVID-19, it would be a great achievement”, says Andreas Bhagwani, CEO Nanologica.
For technical information on Nanologica’s drug delivery platform, please contact:
Kia Bengtsson, Director Drug Development Nanologica
Ph: +46 70 144 36 30 or e-mail: email@example.com
Adam Feiler, CTO Nanologica
Ph: +46 72 353 66 30 or e-mail firstname.lastname@example.org
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size and type of porosity of silica particles. This knowledge is applied within drug development and chromatography (a separation technique used in drug development and drug production). The company’s mission is to contribute to better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.